Use of Zolpidem and Risk of Acute Pyelonephritis in Women: A Population-Based Case-Control Study in Taiwan

Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2017, Pages 376-381

  Hsu, Fan Gen ^a,b   Sheu, Ming Jyh ^a   Lin, Cheng Li ^b,c   Hsieh, Yow Wen ^a,b   Lai, Shih Wei ^b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

acute pyelonephritis; infection; Taiwan; woman; zolpidem

Indexed keywords

BENZODIAZEPINE; ZOLPIDEM; HYPNOTIC SEDATIVE AGENT; PYRIDINE DERIVATIVE;

ACUTE PYELONEPHRITIS; ADULT; AGE DISTRIBUTION; AGED; ALCOHOLISM; ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; RISK FACTOR; TAIWAN; URINARY TRACT INFECTION; VERY ELDERLY; ACUTE DISEASE; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; EPIDEMIOLOGY; MIDDLE AGED; ODDS RATIO; PYELONEPHRITIS; TIME FACTOR;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MIDDLE AGED; ODDS RATIO; PYELONEPHRITIS; PYRIDINES; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84994289080     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.815     Document Type: Article

References (29)

1. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–S10.
2. Lin FY, Chen PC, Liao CH, Hsieh YW, Sung FC. Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep. 2014;37(4):673–679.
3. Dang A, Garg A, Rataboli PV. Role of zolpidem in the management of insomnia. CNS Neurosci Ther. 2011;17(5):387–397.
4. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs. 2005;19(1):65–89.
5. Zdrinca M, Mutiu G, Bogdan M, et al. Effects of alprazolam, zolpidem and zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. Rom J Morphol Embryol. 2011;52(1 Suppl):471–474.
6. Darcourt G, Pringuey D, Salliere D, Lavoisy J. The safety and tolerability of zolpidem—an update. J Psychopharmacol. 1999;13(1):81–93.
7. Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: a nationwide population-based case-control study. Mayo Clin Proc. 2016;91(3):308–315.
8. Kao CH, Sun LM, Liang JA, Chang SN, Sung FC, Muo CH. Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc. 2012;87(5):430–436.
9. Lai SW, Lin CL, Liao KF. Increased relative risk of acute pancreatitis in zolpidem users. Psychopharmacology (Berl). 2015;232(12):2043–2048.
10. Liao KF, Lin CL, Lai SW, Chen WC. Zolpidem use associated with increased risk of pyogenic liver abscess: a case–control study in Taiwan. Medicine (Baltimore). 2015;94(32):e1302.
11. Huang CY, Chou FH, Huang YS, et al. The association between zolpidem and infection in patients with sleep disturbance. J Psychiatr Res. 2014;54:116–120.
12. Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009;5(4):377–383.
13. Torres SR, Frode TS, Nardi GM, et al. Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur J Pharmacol. 2000;408(2):199–211.
14. Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res. 2008;17(3):245–250.
15. Ki M, Park T, Choi B, Foxman B. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol. 2004;160(10):985–993.
16. Bethel J. Acute pyelonephritis: risk factors, diagnosis and treatment. Nurs Stand. 2012;27(5):51–56; quiz 58.
17. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics. 2005;23(11):1123–1142.
18. eHealthMe. Study from FDA and social media reports review: could zolpidem cause pyelonephritis acute? http://www.ehealthme.com/ds/zolpidem/pyelonephritis+acute. Accessed May 2016.
19. National Health Insurance Research Database, Taiwan (English version). http://nhird.nhri.org.tw/en/index.htm. Accessed May 2016.
20. Nicolle LE, Friesen D, Harding GK, Roos LL. Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of diabetes, pregnancy, and aboriginal origin. Clin Infect Dis. 1996;22(6):1051–1056.
21. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex–dependent differences. J Pharmacol Exp Ther. 2000;293(2):435–443.
22. Guo T, Mao G, Zhao L, Xia D, Yang L. Comparative pharmacokinetics of zolpidem tartrate in five ethnic populations of China. Acta Pharm Sin B. 2014;4(2):146–150.
23. Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007;7:42.
24. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun. 2011;25(2):221–229.
25. Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol Ther. 1997;75(3):199–216.
26. Covelli V, Munno I, Decandia P, et al. Effects of benzodiazepines on the immune system. Acta Neurol (Napoli). 1991;13(5):418–423.
27. Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003;56(3):297–304.
28. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther. 2014; 36(11):1676–1701.
29. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142(1):20–27.